贝前列腺素钠联合西洛他唑治疗下肢动脉粥样硬化性疾病的临床分析.PDFVIP

84 ● ● 《中国医学前沿杂志 （电子版）》2016 年第 8 卷第 8 期  论著  贝前列腺素钠联合西洛他唑治疗下肢 动脉粥样硬化性疾病的临床分析 唐鹏，赵素平，李晓青，种莉，李锐 （陕西省人民医院　神经内三科，西安　710068 ） 【摘要】 目的 探讨贝前列腺素钠联合西洛他唑治疗下肢动脉粥样硬化性疾病的临床效果。方法 选 取 2013 年 11 月至 2015 年 10 月就诊于本院的下肢动脉粥样硬化性疾病患者 78 例为研究对象，按随机 数表法将其分为联合治疗组 （贝前列腺素钠与西洛他唑联合治疗，39 例）和单药治疗组 （西洛他唑单 药治疗，39 例），两组患者均治疗 4 周。分别于治疗前及治疗后 4 周进行患者主观症状评分、踝肱指 数 （ABI ）测量和 6 分钟步行试验 （6-MWT ）评定。结果 治疗后 4 周，两组患者主观症状评分均低 P P 于治疗前 （ ＜ 0.05 ），且联合治疗组患者主观症状评分低于单药治疗组 （ ＜ 0.05 ）；两组患者 ABI P P 和 6-MWT 评分均高于治疗前 （ ＜ 0.05 ），但组间比较均无显著差异 （ ＞0.05 ）。结论 贝前列腺素 钠联合西洛他唑治疗下肢动脉粥样硬化性疾病，可改善患者的主观症状，安全性良好。 【关键词】贝前列腺素钠 ；西洛他唑 ；下肢动脉粥样硬化性疾病 ；疗效 Efficacy of beraprost sodium combined with cilostazol in the treatment of lower extremity atherosclerotic disease TANG Peng, ZHAO Su-ping, LI Xiao-qing, CHONG Li, LI Rui (the Third Department of Neurology, Shaanxi Provincial Peoples Hospital, Xian 710068, China) Corresponding author: LI Rui, E-mail: stroke@126.com Abstract Objective 【 】 　To evaluate the therapeutic effects of beraprost sodium combined with cilostazol in the treatment of lower extremity atherosclerotic disease (LEAD). Method　Collected 78 patients with LEAD which in our hospital as research obj ects from November 2013 to October 2015. They were randomly assigned into combined treatment group (beraprost sodium combined with cilostazol, 39 cases) and monotherapy group (cilostazol monotherapy, 39 cases). Both groups were treated for two weeks. Before treatment and 4 weeks after treatment, the subj ective symptoms, ankle or brachial index (ABI) and 6-minute walk test (6- MWT) were assessed betwwen the two groups. Result　Subj ective symptom scores were decreased at 4 weeks after treatment compared with before treatment (P ＜ 0.05), subj ective symptom scores at 4 weeks after treatment were significant